BNP PARIBAS ASSET MANAGEMENT Holding S.A. Has $64.10 Million Stock Position in Gilead Sciences, Inc. (NASDAQ:GILD)

BNP PARIBAS ASSET MANAGEMENT Holding S.A. raised its stake in Gilead Sciences, Inc. (NASDAQ:GILDFree Report) by 38.2% in the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 764,520 shares of the biopharmaceutical company’s stock after purchasing an additional 211,493 shares during the quarter. BNP PARIBAS ASSET MANAGEMENT Holding S.A.’s holdings in Gilead Sciences were worth $64,097,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors and hedge funds have also recently modified their holdings of the company. MQS Management LLC bought a new position in shares of Gilead Sciences in the first quarter valued at approximately $250,000. Axxcess Wealth Management LLC grew its holdings in Gilead Sciences by 24.5% during the first quarter. Axxcess Wealth Management LLC now owns 17,916 shares of the biopharmaceutical company’s stock valued at $1,312,000 after purchasing an additional 3,521 shares during the period. Canada Pension Plan Investment Board grew its holdings in Gilead Sciences by 6.1% during the first quarter. Canada Pension Plan Investment Board now owns 1,410,443 shares of the biopharmaceutical company’s stock valued at $103,315,000 after purchasing an additional 80,666 shares during the period. Epoch Investment Partners Inc. grew its holdings in Gilead Sciences by 18.7% during the first quarter. Epoch Investment Partners Inc. now owns 887,978 shares of the biopharmaceutical company’s stock valued at $65,044,000 after purchasing an additional 139,907 shares during the period. Finally, Lazard Asset Management LLC grew its holdings in Gilead Sciences by 2.6% during the first quarter. Lazard Asset Management LLC now owns 969,733 shares of the biopharmaceutical company’s stock valued at $71,032,000 after purchasing an additional 24,683 shares during the period. 83.67% of the stock is owned by hedge funds and other institutional investors.

Gilead Sciences Price Performance

Shares of GILD opened at $89.84 on Friday. The company has a market cap of $111.96 billion, a price-to-earnings ratio of 998.22, a price-to-earnings-growth ratio of 2.72 and a beta of 0.17. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The company has a 50 day moving average of $87.28 and a two-hundred day moving average of $76.61.

Gilead Sciences (NASDAQ:GILDGet Free Report) last posted its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping the consensus estimate of $1.58 by $0.44. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The business had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. During the same period in the previous year, the firm posted $2.29 earnings per share. The business’s revenue for the quarter was up 7.0% compared to the same quarter last year. As a group, analysts predict that Gilead Sciences, Inc. will post 4.38 earnings per share for the current fiscal year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Investors of record on Friday, December 13th will be issued a dividend of $0.77 per share. The ex-dividend date is Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.43%. Gilead Sciences’s dividend payout ratio (DPR) is presently 3,422.22%.

Analysts Set New Price Targets

GILD has been the subject of several research reports. JPMorgan Chase & Co. increased their price objective on Gilead Sciences from $100.00 to $105.00 and gave the company an “overweight” rating in a report on Thursday, November 7th. The Goldman Sachs Group raised their price target on Gilead Sciences from $74.00 to $84.00 and gave the stock a “neutral” rating in a report on Thursday, November 7th. Wolfe Research started coverage on Gilead Sciences in a report on Friday, November 15th. They issued an “outperform” rating and a $110.00 price target for the company. Barclays raised their price target on Gilead Sciences from $84.00 to $95.00 and gave the stock an “equal weight” rating in a report on Thursday, November 7th. Finally, Daiwa America raised Gilead Sciences to a “hold” rating in a report on Monday. Twelve investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and four have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $95.41.

View Our Latest Stock Report on Gilead Sciences

Insider Buying and Selling

In other Gilead Sciences news, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $83.78, for a total value of $2,459,529.46. Following the completion of the transaction, the insider now owns 78,127 shares of the company’s stock, valued at approximately $6,545,480.06. The trade was a 27.31 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Merdad Parsey sold 25,590 shares of Gilead Sciences stock in a transaction on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the transaction, the insider now directly owns 99,599 shares of the company’s stock, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 56,947 shares of company stock valued at $4,968,674 over the last 90 days. Insiders own 0.16% of the company’s stock.

About Gilead Sciences

(Free Report)

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

Featured Stories

Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILDFree Report).

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.